<DOC>
	<DOC>NCT00683904</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.</brief_summary>
	<brief_title>Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Age ≥20 years Histologic or cytologic diagnosis of advanced nonsmall cell lung cancer (NSCLC) Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent No prior chemotherapycontaining regimens for the treatment of NSCLC Eastern Cooperative Oncology Group performance status of 01 Life expectancy of at least 12 weeks Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1 Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy) Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug Women pregnant or breast feeding Women with a positive pregnancy test result on enrollment or prior to study drug administration Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases Prior radiation must not have included ≥30% of major bonemarrowcontaining areas (pelvis, lumbar spine) Common Terminology Criteria (CTC) Grade 2 or greater neuropathy Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible) Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy. Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months Known history of infection with human immunodeficiency virus Inadequate bone marrow function Inadequate hepatic function Inadequate renal function Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL Known severe hypersensitivity reaction to agents containing carboplatin and other platinum Prior treatment with an epothilone and/or with platinum History of highdose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years On treatment with strong Cytochrome P450 3A4 inhibitor Current imprisonment Compulsorily detention for treatment of psychiatric or physical illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>